The SU2C Catalyst takes a structured and prioritized approach to early-phase clinical studies or translational research in order to accelerate the time to get new treatments to patients and bring together all the key players in a collaborative and strategic manner. The SU2C Catalyst Research Grant: Genentech-Supported project must include atezolizumab, bevacizumab (combinations only), alectinib, cobimetinib, vemurafenib, vismodegib, trastuzumab plus pertuzumab (must be in this combination only), obinutuzumab, emactuzumab, anti-CD40, or idasanutlin, alone or in combination with other compounds, biologics, diagnostics, or devices intended as therapeutic interventions, and/or methods for biomarker identification in the following thematic areas of research:
- Role of negative or positive regulatory molecules (biomarkers) as predictors of response to immune therapies in the setting of preoperative versus metastatic clinical settings.
- Neoantigen identification and predictability of clinical effects of immune therapies (checkpoints, adjuvants, endogenous versus exogenous vaccines).
- Duration of immune therapies, including after response or disease progression, and impact on immune biomarkers.
If a product is proposed for use that is marketed or is under development by another company, SU2C will act as an honest broker to secure the necessary agreements. To advance science rapidly and with robust input, multi-investigator, multi-institutional projects are required. In accordance with SU2C's mission, the project must be designed to accelerate the application of therapeutic agents or methods to the clinic (i.e., lead to patient involvement within the timeframe of the grant) and deliver near-term patient benefit through investigation by a collaborative SU2C Catalyst Genentech Team of expert investigators. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care. An emphasis on early phase, signal-finding clinical trials is encouraged. Clinical trials must be planned so that the final patient is enrolled by the end of the grant term.